SARS-CoV-2 vaccine-related adverse events in Zimbabwe: the need to strengthen pharmacovigilance in resource-limited settings

Grant Murewanhema; Tafadzwa Dzinamarira; Roda Madziva; Helena Herrera; Godfrey Musuka

doi:10.1002/pds.5393

SARS-CoV-2 vaccine-related adverse events in Zimbabwe: the need to strengthen pharmacovigilance in resource-limited settings

Grant Murewanhema, Tafadzwa Dzinamarira, Roda Madziva, Helena Herrera, Godfrey Musuka

Institute of Life Sciences and Healthcare

Research output: Contribution to journal › Letter › peer-review

26 Downloads (Pure)

Original language	English
Journal	Pharmacoepidemiology and Drug Safety
DOIs	https://doi.org/10.1002/pds.5393
Publication status	Published - 9 Dec 2021

Keywords

pharmacovigilance
Covid-19
limited resources

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/pds.5393

2021 - SARS‐CoV‐2 vaccine‐related adverse events in Zimbabwe
This is the peer reviewed version of the following article: Murewanhema, G., Dzinamarira, T., Madziva, R., Herrera, H. and Musuka, G. (2022), SARS-CoV-2 vaccine-related adverse events in Zimbabwe: The need to strengthen pharmacovigilance in resource-limited settings. Pharmacoepidemiology and Drug Safety, which has been published in final form at 10.1002/pds.5393. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.
Accepted author manuscript (Post-print), 298 KB

Cite this

@article{4aaef9b542074d36a25188a02df62284,

title = "SARS-CoV-2 vaccine-related adverse events in Zimbabwe: the need to strengthen pharmacovigilance in resource-limited settings",

keywords = "pharmacovigilance, Covid-19, limited resources",

author = "Grant Murewanhema and Tafadzwa Dzinamarira and Roda Madziva and Helena Herrera and Godfrey Musuka",

note = "Article does not have an abstract. 12 months embargo. This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley{\textquoteright}s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.",

year = "2021",

month = dec,

day = "9",

doi = "10.1002/pds.5393",

language = "English",

journal = "Pharmacoepidemiology and Drug Safety",

issn = "1053-8569",

publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - SARS-CoV-2 vaccine-related adverse events in Zimbabwe: the need to strengthen pharmacovigilance in resource-limited settings

AU - Murewanhema, Grant

AU - Dzinamarira, Tafadzwa

AU - Madziva, Roda

AU - Herrera, Helena

AU - Musuka, Godfrey

N1 - Article does not have an abstract. 12 months embargo. This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.

PY - 2021/12/9

Y1 - 2021/12/9

KW - pharmacovigilance

KW - Covid-19

KW - limited resources

U2 - 10.1002/pds.5393

DO - 10.1002/pds.5393

M3 - Letter

SN - 1053-8569

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

ER -